Arkadius MBA - MorphoSys Chief Officer

Executive

Arkadius MBA is Chief Officer of MorphoSys AG ADR
Phone49 89 899 27 0
Webhttps://www.morphosys.com

MorphoSys Management Efficiency

The company has Return on Asset of (0.1384) % which means that on every $100 spent on assets, it lost $0.1384. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (1.838) %, meaning that it generated no profit with money invested by stockholders. MorphoSys' management efficiency ratios could be used to measure how well MorphoSys manages its routine affairs as well as how well it operates its assets and liabilities.
MorphoSys AG ADR has 635.93 M in debt with debt to equity (D/E) ratio of 2.32, meaning that the company heavily relies on borrowing funds for operations. MorphoSys AG ADR has a current ratio of 2.92, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Note however, debt could still be an excellent tool for MorphoSys to invest in growth at high rates of return.

Similar Executives

Showing other executives

EXECUTIVE Age

Robert SmithGossamer Bio
55
John JDEdgewise Therapeutics
60
Crystal ZuckermanPmv Pharmaceuticals
N/A
Yalonda JDGeneration Bio Co
52
Philip JDMonte Rosa Therapeutics
45
Barbara JDKronos Bio
65
Harp MBAVaxcyte
51
Michael NasoCentury Therapeutics
N/A
MBA MDReplimune Group
58
Robert MDLyra Therapeutics
N/A
Nick MDCentury Therapeutics
N/A
Ray KnoxLyra Therapeutics
N/A
Michael CPANuvectis Pharma
48
Douglas CPACentury Therapeutics
N/A
JD EsqImmunocore Holdings
57
Elvia CowanVaxcyte
51
Kevin JohnstonCullinan Oncology LLC
N/A
Timothy LowingerMersana Therapeutics
60
Mark MosslerC4 Therapeutics
51
Jolie JDC4 Therapeutics
47
Matt CravetsGossamer Bio
N/A
MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. The company was founded in 1992 and is headquartered in Planegg, Germany. Morphosys operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 648 people. MorphoSys AG ADR (MOR) is traded on NASDAQ Exchange in USA and employs 464 people.

Management Performance

MorphoSys AG ADR Leadership Team

Elected by the shareholders, the MorphoSys' board of directors comprises two types of representatives: MorphoSys inside directors who are chosen from within the company, and outside directors, selected externally and held independent of MorphoSys. The board's role is to monitor MorphoSys' management team and ensure that shareholders' interests are well served. MorphoSys' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, MorphoSys' outside directors are responsible for providing unbiased perspectives on the board's policies.
Gnter Wellnhofer, Head Operations
Maria Castresana, VP HR
Anja Pomrehn, VP Relations
Lukas Gilgen, Chief Officer
Lucinda Crabtree, CFO Board
Charlotte Lohmann, Compliance Legal
Sung Lee, CFO Board
Tim MD, Chief Officer
Marlies Sproll, Chief Scientific Officer, Member of the Management Board
Julia Neugebauer, Head Relations
Barbara KrebsPohl, Chief Officer
Arkadius MBA, Chief Officer
Ralf Ostendorp, Head CMC
Harald Watzka, Head Management
Lara Weber, Corp Controlling
JeanPaul MD, MD Board
Margit Urban, Head Technologies
Yen Chua, Head Operations
Klaus Wall, Head Tax
Thomas Biegi, VP Communications

MorphoSys Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is MorphoSys a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with MorphoSys

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if MorphoSys position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in MorphoSys will appreciate offsetting losses from the drop in the long position's value.

Moving against MorphoSys Stock

  0.84MMV MultiMetaVerse HoldingsPairCorr
  0.83THCPU Thunder Bridge CapitalPairCorr
  0.77OPTX Syntec Optics Holdings TrendingPairCorr
  0.64HSDT Helius Medical TechnPairCorr
  0.52XMTR XometryPairCorr
The ability to find closely correlated positions to MorphoSys could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace MorphoSys when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back MorphoSys - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling MorphoSys AG ADR to buy it.
The correlation of MorphoSys is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as MorphoSys moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if MorphoSys AG ADR moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for MorphoSys can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.
You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.

Other Consideration for investing in MorphoSys Stock

If you are still planning to invest in MorphoSys AG ADR check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the MorphoSys' history and understand the potential risks before investing.
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk